# KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment

> **NCT03662126** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Kartos Therapeutics, Inc.** · enrollment: 385 (estimated)

## Conditions studied

- Primary Myelofibrosis (PMF)
- Post-Polycythemia Vera MF (Post-PV-MF)
- Post-Essential Thrombocythemia MF (Post-ET-MF)

## Interventions

- **DRUG:** KRT-232
- **DRUG:** Best Available Therapy (BAT)

## Key facts

- **NCT ID:** NCT03662126
- **Lead sponsor:** Kartos Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-01-15
- **Primary completion:** 2023-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 385 (ESTIMATED)
- **Last updated:** 2023-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03662126

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03662126, "KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT03662126. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*